Clinical Trials Logo

Mucositis clinical trials

View clinical trials related to Mucositis.

Filter by:

NCT ID: NCT03497065 Completed - Dental Plaque Clinical Trials

Dental Implant Care and Oral Hygiene Practices

Start date: April 1, 2017
Phase:
Study type: Observational

Objective: This study investigated how patients' knowledge, attitude, and perceptions influence their oral hygiene practices as well as peri-implant health. Materials and Methods: Participants with single implant crowns placed in 2007-2011 completed a questionnaire that examined their knowledge, attitude, and perceptions on oral hygiene practices and peri-implant health before receiving a periodontal examination, prophylaxis, and oral hygiene education. Clinical parameters recorded were peri-implant probing depths and plaque index, width of keratinized mucosa, implant crown characteristics, reason for tooth loss, and diagnosis of peri-implant health.

NCT ID: NCT03492749 Active, not recruiting - Bone Marrow Disease Clinical Trials

Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation

Start date: February 2016
Phase:
Study type: Observational [Patient Registry]

Busulfan (Bu) has been widely used for the treatment of neoplastic and non-neoplastic hematological disturbances, with satisfactory results in terms of successful hematopoietic stem cell transplantation (HSCT). Individual monitoring of the Bu dosage, which is done by means of various blood sample collections, is necessary for the purpose of attaining ideal therapeutic levels and minimizing systemic toxicity. This procedure sometimes becomes costly to and uncomfortable for the patient. Saliva has been analyzed as a possible alternative fluid for this monitoring.

NCT ID: NCT03490396 Recruiting - Oral Mucositis Clinical Trials

Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients

Start date: April 9, 2018
Phase: Phase 4
Study type: Interventional

Patients receiving high-dose chemotherapy/conditioning prior to stem cell transplantation (SCT) are at high risk for developing painful lesions in the oral cavity, known as oral mucositis (OM). In this high risk adult population, the study objectives are to investigate the efficacy and tolerability of Gelclair® (GEL; an FDA cleared medical device indicated for the management of painful oral lesions) and ideal timing of initiation of therapy (at the time of conditioning or after mild OM is diagnosed) for the management of oral mucositis (OM), relative to a commercially available compounded mouth wash (First® Mouthwash BLM "Magic Mouth Wash"; MMW) initiated after mild OM is diagnosed. The study may be adapted based on an interim analysis and recommendations of the interim data review committee.

NCT ID: NCT03480971 Not yet recruiting - Mucositis Clinical Trials

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol

Start date: March 2018
Phase: Phase 2
Study type: Interventional

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.

NCT ID: NCT03469284 Not yet recruiting - Clinical trials for Diseases of Oral Cavity Salivary Glands and Jaws

MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Start date: May 2018
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical research study is to compare methylene blue (an oral rinse) to standard therapy to learn if one is better, the same, or worse than the other in controlling mucositis (mouth blisters/sores). Standard therapy may include regular analgesics (numbing medications) and mouth rinses. This is an investigational study. Methylene blue is FDA approved and commercially available to treat methemoglobinemia (a type of blood disorder). It is considered investigational to use methylene blue to treat mucositis. The study doctor can explain how methylene blue is designed to work. Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.

NCT ID: NCT03461354 Recruiting - Clinical trials for Head and Neck Cancer

MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

Start date: March 2018
Phase: Phase 2
Study type: Interventional

This study will examine if the administration of prophylactic MucoLox formulation versus sodium bicarbonate mouthwash in subjects with head/neck cancer receiving radiation ± chemotherapy will result in significantly fewer subjects experiencing severe mucositis.

NCT ID: NCT03444675 Recruiting - Enteritis Clinical Trials

The Endoscopic Assesment of Intestinal Grafts

INTEGRATE
Start date: April 29, 2014
Phase: N/A
Study type: Observational

The study validates prospectively a new endoscopic scoring system (Gothenburg Intestinal Transplant Endoscopy Score, GITES) designed to summarize and stratify the abnormal ileal endoscopic findings after intestinal transplantation. GITES is a five-tier, four grade score which asseses mucosal friability, mucosal erythema and mucosal injury (ulcerations) as well as villous changes according to severity. These features (i.e., endoscopic descriptors) are also grouped from mild to very severe in the same sequence as observed during the progression of several pathologic conditions encountered after intestinal transplantation (acute rejection, infectious enteritis).

NCT ID: NCT03421717 Active, not recruiting - Periimplantitis Clinical Trials

The Effect of Peri-implant Surgery and Chair-side Supportive Post Surgical Peri-implant Therapy

Start date: November 1, 2012
Phase: N/A
Study type: Interventional

Peri-implantitis is defined as inflammation in the mucosa surrounding an oral implant with loss of supporting bone. The goals of peri-implantitis treatment are to resolve inflammation and to arrest the progression of disease. It is important to systematically gather information on the effect of surgical peri-implant treatment and to assess different protocols regarding chair-side maintenance of peri-implant tissue after surgery The aims of this clinical investigation are to evaluate the clinical, microbiological and radiographic outcomes of surgical treatment of peri-implantitis and to evaluate the efficacy of 2 supportive treatment protocols based on the use of titanium cyrettes or by the use of a flexible, biodegradable chitosan brush. Furthermore, to evaluate the impact of this therapy on selected biochemical markers associated with chronic inflammation and bone tissue destruction.

NCT ID: NCT03416582 Not yet recruiting - Lung Cancer Clinical Trials

Nurse Intervention To Impact Mucositis Severity And Prevent Dehydration DEHYDRATION

Start date: June 2018
Phase: N/A
Study type: Interventional

This is a descriptive mixed method pilot study to determine the feasibility of a tailored nurse-delivered telephone intervention designed to impact mucositis symptom severity and prevent dehydration in lung cancer patients undergoing chemoradiation, therefore reducing overall symptom severity and improving quality of life. Secondary purposes for this study are to investigate if the nursing intervention can decrease lung cancer patients' unscheduled medical visits between chemoradiation treatments.

NCT ID: NCT03400475 Completed - Clinical trials for Peri-implant Mucositis

Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis

Start date: April 23, 2015
Phase: Phase 2
Study type: Interventional

This study seeks to test the recently discovered anti-inflammatory action of statins on inflamed mucosa surrounding dental implants. Hypothesis: The application of 1.2% simvastatin gel will decrease peri-implant inflammation. The pilot study will involve 44 subjects divided into a test and control group. The test group shall receive topical simvastatin gel administered around the implant with a blunt tipped needle. The control group will receive a placebo. Inflammatory state shall be determined at baseline as well as follow up visits at 24 hours, 1 week, and 1 month by clinical indices of inflammation as well as biochemical markers of inflammation gathered from around the implants.